๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis

โœ Scribed by Barbara E. Drevlow; Rosa Lovis; Mary Ann Haag; James M. Sinacore; Cindy Jacobs; Consuelo Blosche; Alan Landay; Larry W. Moreland; Richard M. Pope

Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
724 KB
Volume
39
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Combination benefit of treatment with th
Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis
โœ Alison M. Bendele; Elizabeth S. Chlipala; Jon Scherrer; Janet Frazier; Gina Senn ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 695 KB

Objective. To determine the potential for additive or synergistic effects of combination therapy with the recombinant anticytokine agents interleukin-1 receptor antagonist (IL-1Ra) and PEGylated soluble tumor necrosis factor receptor type I (PEG sTNFRI) in established type II collagen-induced arthri

Dysregulation of the in vivo production
Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis pathogenetic implications
โœ Ian C. Chikanza; Pascal Roux-Lombard; Jean-Michel Dayer; Gabriel S. Panayi ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 636 KB

## Objective: Patients with rheumatoid arthritis (ra) have defective hypothalamic responses to inflammation, possibly because of excessive production of cytokine inhibitor, which could blunt the effects of cytokines on the hypothalamus, or because of an imbalance between interleukin-1 beta (il-1 be